DCB Catheter Maintains Patent AV Fistula
By HospiMedica International staff writers Posted on 13 Sep 2017 |
An innovative drug coated balloon (DCB) catheter helps clear the stenotic lesions that form in dialysis arteriovenous (AV) fistulae placed in end stage renal disease (ESRD) dialysis patients.
An innovative drug coated balloon (DCB) catheter helps clear the stenotic lesions that form in dialysis arteriovenous (AV) fistulae placed in end stage renal disease (ESRD) dialysis patients.
The C. R. Bard (Murray Hill, NJ, USA) Lutonix 035 DCB percutaneous transluminal angioplasty (PTA) catheter is coated with paclitaxel, an anti-proliferative drug commonly used to prevent arterial restenosis. The highly efficient formulation of paclitaxel, polysorbate, and sorbitol allows the low profile DCB catheter to deliver a therapeutic dose to the artery wall in a single, short inflation, while keeping the dose of paclitaxel on the balloon itself as low as possible.
The Lutonix 035 DCB catheter is designed to minimize the size of the access site, while maintaining ease-of-use. It is available in lengths of 40, 60, 80, 100, 120, and 150 mm, and in diameters of 4-6 mm (in catheters up to 150 mm in length), and 7 mm in catheters up to 60 mm in length. The DCB also features the GeoAlign marking system, a simple-to-use, non-radiopaque ruler on the catheter shaft itself that facilitates repeatable catheter alignment at the lesion, and increase procedure efficiency by minimizing fluoroscopy exposure.
“For patients undergoing hemodialysis for kidney failure, who already spend a significant portion of their time undergoing dialysis and other treatments, repeated reinterventions to maintain AV access can be an added burden, with many patients returning as frequently as every other month,” said Professor Scott Trerotola, MD, of the University of Pennsylvania (Penn; Philadelphia, USA). “The Lutonix 035 DCB catheter…is intended to offer patients with end-stage renal disease fewer interruptions in treatment and less time undergoing access maintenance, potentially leading to improved patient satisfaction and quality of life.”
ESRD is the fifth and last stage of chronic kidney disease (CKD), signifying that the kidneys are working at less than 10% capacity, and that dialysis or a kidney transplant are necessary. ESRD is also associated with an increased incidence and prevalence of a wide range of cardiovascular disease, including stroke, coronary artery disease, congestive heart failure (CHF), atrial fibrillation (AF), sudden cardiac death, pulmonary hypertension, and valvular heart disease.
The C. R. Bard (Murray Hill, NJ, USA) Lutonix 035 DCB percutaneous transluminal angioplasty (PTA) catheter is coated with paclitaxel, an anti-proliferative drug commonly used to prevent arterial restenosis. The highly efficient formulation of paclitaxel, polysorbate, and sorbitol allows the low profile DCB catheter to deliver a therapeutic dose to the artery wall in a single, short inflation, while keeping the dose of paclitaxel on the balloon itself as low as possible.
The Lutonix 035 DCB catheter is designed to minimize the size of the access site, while maintaining ease-of-use. It is available in lengths of 40, 60, 80, 100, 120, and 150 mm, and in diameters of 4-6 mm (in catheters up to 150 mm in length), and 7 mm in catheters up to 60 mm in length. The DCB also features the GeoAlign marking system, a simple-to-use, non-radiopaque ruler on the catheter shaft itself that facilitates repeatable catheter alignment at the lesion, and increase procedure efficiency by minimizing fluoroscopy exposure.
“For patients undergoing hemodialysis for kidney failure, who already spend a significant portion of their time undergoing dialysis and other treatments, repeated reinterventions to maintain AV access can be an added burden, with many patients returning as frequently as every other month,” said Professor Scott Trerotola, MD, of the University of Pennsylvania (Penn; Philadelphia, USA). “The Lutonix 035 DCB catheter…is intended to offer patients with end-stage renal disease fewer interruptions in treatment and less time undergoing access maintenance, potentially leading to improved patient satisfaction and quality of life.”
ESRD is the fifth and last stage of chronic kidney disease (CKD), signifying that the kidneys are working at less than 10% capacity, and that dialysis or a kidney transplant are necessary. ESRD is also associated with an increased incidence and prevalence of a wide range of cardiovascular disease, including stroke, coronary artery disease, congestive heart failure (CHF), atrial fibrillation (AF), sudden cardiac death, pulmonary hypertension, and valvular heart disease.
Latest Surgical Techniques News
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing
- Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery
- Robotic Nerve ‘Cuffs’ Could Treat Various Neurological Conditions
- Flexible Microdisplay Visualizes Brain Activity in Real-Time To Guide Neurosurgeons
- Next-Gen Computer Assisted Vacuum Thrombectomy Technology Rapidly Removes Blood Clots
- Hydrogel-Based Miniaturized Electric Generators to Power Biomedical Devices
- Custom 3D-Printed Orthopedic Implants Transform Joint Replacement Surgery